Another disappointing result for vitamin D3, this time looking at metastatic colorectal cancer progression and survival. For years, there was hope that taking high doses of vitamin D3 would help in preventing all sorts of cancers or would help in the treatment of cancer. But the studies keep finding no effects from vitamin D3 supplements.
Researchers found that adding high dose vitamin D3 to standard chemotherapy plus bevacizumab did not improve progression-free survival (PFS) in patients with previously untreated metastatic colorectal cancer, when compared to those who received the same treatment except that they received a daily standard dose vitamin D3 supplement.
High dose vitamin D3 was 8000 IU daily for 14 days, followed by 4000 IU daily. Standard dose vitamin D3 (the control group) was 400 IU daily.
Excerpts from Medscape: Does High-Dose Vitamin D3 Supplementation Improve CRC Survival?
High-dose vitamin D3 supplementation added to standard chemotherapy plus bevacizumab does not improve progression-free survival (PFS) compared with standard-dose vitamin D3 in patients with previously untreated metastatic colorectal cancer (mCRC). Among 455 randomized patients, median PFS was 11.8 months in the high-dose group vs 10.3 months in the standard-dose group, with no significant differences in objective response rates or overall survival. ...continue reading "Another Disappointing Vitamin D3 and Cancer Result"